Drug
HhAntag691 clinical trials
Also written Vismodegib, GDC-0449, Erivedge and RO5450815.
- studies test it
- 78
- open now
- 8
- in phase 3
- 0
- first study started
- 2007
Keep track of what changes. Save the HhAntag691 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
78 studies that test it; most in 2009 (13)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 13 |
| 2010 | 11 |
| 2011 | 2 |
| 2012 | 7 |
| 2013 | 8 |
| 2014 | 6 |
| 2015 | 6 |
| 2016 | 7 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 4 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 5
- Phase 1
- 23
- Phase 2
- 54
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 57
National Cancer Institute (NCI) (18) · Genentech, Inc. (13) · Hoffmann-La Roche (8) · University Hospital, Lille (2) · UCSF Benioff Children's Hospital Oakland (2) · Mayo Clinic (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University of Arizona (2)
Often tested with
Tested in the same studies.
Pertuzumab (8) · Atezolizumab (8) · Trastuzumab (7) · Erlotinib (7) · Alectinib (7) · Palbociclib (6) · Vemurafenib (6) · Cobimetinib (6)
Studies
Open first, then newest update. How each study uses HhAntag691 is read from its arms, and is right about nine times in ten.
Testing it · 78
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT02523014Written as Vismodegib
- Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal CancerRecruitingPhase 2Ronald BuckanovichNCT05538091Written as Vismodegib
- Adaptive Therapy of Vismodegib in Advanced Basal Cell CarcinomaRecruitingEarly Phase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05651828Written as Vismodegib 150 MG Oral Capsule
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Written as Vismodegib
- Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell CarcinomaRecruitingPhase 2University Hospital, LilleNCT05561634Written as Vismodegib
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingPhase 2Ulrik LassenNCT04341181Written as Vismodegib
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245Written as Vismodegib
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as Vismodegib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Vismodegib
- Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT06357988Written as Vismodegib
- Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerSuspendedPhase 1Dwight OwenNCT06616623Written as Vismodegib
- GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by SurgeryActive, not recruitingPhase 1National Cancer Institute (NCI)NCT00878163Written as Vismodegib
- Vismodegib in Treating Patients With Advanced ChondrosarcomasActive, not recruitingPhase 2National Cancer Institute (NCI)NCT01267955Written as Vismodegib
- A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive StageCompletedPhase 2National Cancer Institute (NCI)NCT00887159Written as Vismodegib
- Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1CompletedPhase 4University Hospital, BordeauxNCT03610022Written as Treatment with vismodegib
- A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell CarcinomaCompletedPhase 2Genentech, Inc.NCT00833417Written as Vismodegib 150 mg
- A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer StudyCompletedPhase 2Genentech, Inc.NCT00959647Written as Vismodegib
- Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)CompletedPhase 2University Hospital, LilleNCT02667574Written as ERIVEDGE
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedPhase 2Hoffmann-La RocheNCT03498521Written as Vismodegib
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed MedulloblastomaActive, not recruitingPhase 2St. Jude Children's Research HospitalNCT01878617Written as Vismodegib
See all 78 studies that test HhAntag691 →
Given in every arm · 2 — HhAntag691 is usual care beside what is tested
- To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell CarcinomaRecruitingPhase 2Stamford Pharmaceuticals, Inc.NCT06344052Written as Vismodegib
- Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AMLCompletedPhase 2Sarit AssoulineNCT02073838Written as Vismodegib
Codes
What other systems call HhAntag691 · ClinicalTrials.gg INT005390
- RxNorm 1242987One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| RxNorm | 1242987 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.